| Code | CSB-RA884484MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of KVA-12.1, targeting VSIR (also known as VISTA, V-domain Ig suppressor of T cell activation)—a type I transmembrane immunoregulatory receptor that functions as an immune checkpoint. VISTA is prominently associated with myeloid-lineage cells (including MDSCs, monocytes/macrophages) and is also described on T-cell compartments (notably including naïve T cells), where it helps maintain immune quiescence and suppress excessive activation. In tumor settings, VISTA-linked signaling is frequently discussed as a contributor to myeloid-mediated immunosuppression and an axis of checkpoint resistance biology within the tumor microenvironment.
KVA-12.1 is described as a fully human anti-VISTA monoclonal antibody being developed for immuno-oncology, including evaluation in monotherapy and combination with anti–PD-1 strategies. This biosimilar provides the antibody component alone, enabling researchers to investigate VISTA checkpoint biology—such as VISTA-associated suppression of T-cell effector function, regulation of MDSC-mediated inhibition, and target engagement effects on myeloid/T-cell crosstalk—independent of other therapeutic agents. It also supports assay development around VISTA–ligand pathway modulation (e.g., interactions reported with partners like PSGL-1 or VSIG3) and exploratory studies evaluating VISTA/VSIR as a biomarker or mechanistic driver in immunosuppressive microenvironments.
There are currently no reviews for this product.